NCT00447525

Brief Summary

Primary objective: To demonstrate the non inferiority between REVAXIS® and DT Polio® when given as a second booster to healthy 6 year-old children . Secondary objectives:

  • Additional immunogenicity assessments.
  • To describe the safety profile of a single dose of REVAXIS® or DT-Polio®

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
760

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Feb 2007

Shorter than P25 for phase_3

Geographic Reach
1 country

64 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2007

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 12, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 14, 2007

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2008

Completed
Last Updated

September 11, 2017

Status Verified

September 1, 2017

Enrollment Period

11 months

First QC Date

March 12, 2007

Last Update Submit

September 8, 2017

Conditions

Keywords

Prevention of : Diphtheria, Tetanus and Poliomyelitis

Study Arms (2)

1

EXPERIMENTAL
Biological: REVAXIS®

2

ACTIVE COMPARATOR
Biological: DT-Polio®

Interventions

REVAXIS®BIOLOGICAL
1
DT-Polio®BIOLOGICAL
2

Eligibility Criteria

Age6 Years - 6 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Healthy child without chronic severe disease of either gender,
  • year-old child on vaccination day,
  • Child previously vaccinated with three doses of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination within the first 6 months of life and a booster dose of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination at 16 - 18 months of life (±2 months),
  • Consent form signed by both parents, or by the legal representative, properly informed about the study.

You may not qualify if:

  • Child who had received less or more than 4 doses of a diphtheria, tetanus and/or poliomyelitis containing vaccine,
  • Previous clinical or bacteriological diagnosis of diphtheria, tetanus or poliomyelitis,
  • Child who had received any vaccine in the previous 30 days or with a vaccination scheduled during the course of the study,
  • Child who present with immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity,
  • Child who had received within the previous 150 days or who will receive during the course of the study, any immunoglobulins or blood derived products,
  • Child with true hypersensitivity to at least one of the components of a study vaccine or to streptomycin, neomycin or polymixin B,
  • Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition,
  • Child who had presented severe hypersensitivity following an earlier immunization against diphtheria and/or tetanus,
  • Known history of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection,
  • Acute severe febrile illness and/or oral temperature ≥37.5°C at the time of vaccination

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (64)

Unknown Facility

Albertville, 95880, France

Location

Unknown Facility

Albi, 81000, France

Location

Unknown Facility

Angers, 49100, France

Location

Unknown Facility

Annecy, 74000, France

Location

Unknown Facility

Anzin, 59410, France

Location

Unknown Facility

Arras, 62000, France

Location

Unknown Facility

Asnières, 92600, France

Location

Unknown Facility

Avion, 62210, France

Location

Unknown Facility

Bassens, 33530, France

Location

Unknown Facility

Bersée, 59235, France

Location

Unknown Facility

Besançon, 25000, France

Location

Unknown Facility

Blois, 41000, France

Location

Unknown Facility

Boulogne, 92100, France

Location

Unknown Facility

Brest, 29200, France

Location

Unknown Facility

Broglie, 27270, France

Location

Unknown Facility

Caen, 14000, France

Location

Unknown Facility

Chalon-en-champagne, 51000, France

Location

Unknown Facility

Champdeniers, 79220, France

Location

Unknown Facility

Chigny-les-Roses, 51500, France

Location

Unknown Facility

Cholet, 49300, France

Location

Unknown Facility

Claix, 38640, France

Location

Unknown Facility

Clamart, 92141, France

Location

Unknown Facility

Collombey Les Belles, 54170, France

Location

Unknown Facility

Draguignan, 83300, France

Location

Unknown Facility

Enghien-les-Bains, 95880, France

Location

Unknown Facility

Floirac, 33270, France

Location

Unknown Facility

Frouard, 54390, France

Location

Unknown Facility

Haguenau, 67500, France

Location

Unknown Facility

Illkirch-Graffenstaden, 67400, France

Location

Unknown Facility

Issy-les-Moulineaux, 92130, France

Location

Unknown Facility

La Neuville-Roy, 60190, France

Location

Unknown Facility

Laon, 02000, France

Location

Unknown Facility

Le Havre, 76600, France

Location

Unknown Facility

Les Pieux, 50340, France

Location

Unknown Facility

Louverné, 53950, France

Location

Unknown Facility

Louvigné-de-Bais, 35680, France

Location

Unknown Facility

Manduel, 30129, France

Location

Unknown Facility

Marcq-en-barouel, 59700, France

Location

Unknown Facility

Maromme, 76150, France

Location

Unknown Facility

Marseille, 13004, France

Location

Unknown Facility

Miniac-Morvan, 35540, France

Location

Unknown Facility

Montpellier, 34080, France

Location

Unknown Facility

Montsang/orge, 91390, France

Location

Unknown Facility

Morangis, 91420, France

Location

Unknown Facility

Nancy, 54000, France

Location

Unknown Facility

Nantes, 44300, France

Location

Unknown Facility

Nogent-sur-Marne, 94130, France

Location

Unknown Facility

Ostwald, 67540, France

Location

Unknown Facility

Paris, 75013, France

Location

Unknown Facility

Paris, 75019, France

Location

Unknown Facility

Plouzané, 29280, France

Location

Unknown Facility

Poitiers, 86000, France

Location

Unknown Facility

Pont-à-Mousson, 54700, France

Location

Unknown Facility

Quimper, 29000, France

Location

Unknown Facility

Rouen, 76000, France

Location

Unknown Facility

Rouen, 76100, France

Location

Unknown Facility

Saint Sebastien Sur Loir, 44230, France

Location

Unknown Facility

Saint-Ouen, 93400, France

Location

Unknown Facility

Saint-Raphaël, 83700, France

Location

Unknown Facility

Sanary Mer, 83110, France

Location

Unknown Facility

Sèvres, 92310, France

Location

Unknown Facility

Strasbourg, 67000, France

Location

Unknown Facility

Toulouse, 31000, France

Location

Unknown Facility

Villemomble, 93250, France

Location

Related Publications (1)

  • Gajdos V, Soubeyrand B, Vidor E, Richard P, Boyer J, Sadorge C, Fiquet A. Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS ((R))) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio ((R))) given as a booster dose at 6 years of age. Hum Vaccin. 2011 May;7(5):549-56. doi: 10.4161/hv.7.5.14982. Epub 2011 May 1.

MeSH Terms

Conditions

DiphtheriaTetanusPoliomyelitis

Condition Hierarchy (Ancestors)

Corynebacterium InfectionsActinomycetales InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsClostridium InfectionsMyelitisCentral Nervous System InfectionsEnterovirus InfectionsPicornaviridae InfectionsRNA Virus InfectionsVirus DiseasesCentral Nervous System DiseasesNervous System DiseasesSpinal Cord DiseasesNeuroinflammatory DiseasesNeuromuscular Diseases

Study Officials

  • Medical Director

    Sanofi Pasteur, a Sanofi Company

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 12, 2007

First Posted

March 14, 2007

Study Start

February 1, 2007

Primary Completion

January 1, 2008

Study Completion

January 1, 2008

Last Updated

September 11, 2017

Record last verified: 2017-09

Locations